PRLD Logo

Prelude Therapeutics Incorporated (PRLD) 

NASDAQ
Market Cap
$72.91M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
678 of 776
Rank in Industry
366 of 433

Largest Insider Buys in Sector

PRLD Stock Price History Chart

PRLD Stock Performance

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high …

Insider Activity of Prelude Therapeutics Incorporated

Over the last 12 months, insiders at Prelude Therapeutics Incorporated have bought $0 and sold $0 worth of Prelude Therapeutics Incorporated stock.

On average, over the past 5 years, insiders at Prelude Therapeutics Incorporated have bought $42.86M and sold $3.47M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 900 shares for transaction amount of $4,779 was made by Vaddi Krishna (CEO) on 2023‑05‑25.

List of Insider Buy and Sell Transactions, Prelude Therapeutics Incorporated

2023-05-25PurchaseCEO
900
0.0019%
$5.31$4,779-27.80%
2023-05-24PurchaseCEO
1,000
0.002%
$5.01$5,011-26.36%
2023-05-24PurchaseChief Legal Officer, Corp Sec.
2,400
0.0053%
$5.39$12,936-26.36%
2023-05-23PurchaseCEO
11,856
0.0257%
$5.63$66,749-30.28%
2023-05-23PurchaseChief Financial Officer
5,000
0.0106%
$5.50$27,500-30.28%
2023-05-22Purchase
869,565
1.9148%
$5.75$5M-30.53%
2023-05-22Purchase
869,565
1.9148%
$5.75$5M-30.53%
2023-04-06SalePresident, CMO
13,280
0.0276%
$6.12$81,274-36.53%
2022-12-20PurchaseCEO
19,188
0.0417%
$5.13$98,446-6.63%
2022-12-08PurchaseChief Financial Officer
10,000
0.0199%
$4.76$47,600-1.98%
2022-06-01PurchaseChief Financial Officer
10,000
0.0213%
$4.23$42,300+48.69%
2021-12-15SaleEVP, Chief of Clinical Affairs
28,751
0.061%
$13.00$373,763-48.80%
2021-12-14PurchaseEVP, Head of Chemistry
4,000
0.0085%
$11.60$46,400-42.68%
2021-12-13PurchaseEVP, Head of Chemistry
4,000
0.0087%
$12.12$48,480-43.56%
2021-11-16SaleEVP, Chief of Clinical Affairs
28,751
0.0619%
$15.88$456,532-54.90%
2021-10-05SaleChief Medical Officer
15,000
0.0336%
$30.96$464,350-74.15%
2021-09-07SaleChief Medical Officer
15,000
0.0314%
$36.69$550,283-77.25%
2021-09-02SaleEVP and Chief of Business Oper
17,000
0.0396%
$41.68$708,493-77.31%
2021-08-27SaleChief Scientific Officer
6,014
0.0124%
$35.91$215,967-76.42%
2021-08-26SaleChief Scientific Officer
1,700
0.0038%
$35.19$59,819-74.05%

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC
10119756
18.3914%
$1.3350<0.0001%
Bonita David P
10119756
18.3914%
$1.3350+9.05%
BAKER BROS. ADVISORS LP
5212371
9.4728%
$1.3340+34.76%
Vaddi KrishnaCEO
1067275
1.9396%
$1.3340<0.0001%
Combs AndrewEVP, Head of Chemistry
268380
0.4877%
$1.3330<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$51.71M19.8610.91M0%+$00.4
Baker Bros Advisors LP$47.99M18.4310.12M0%+$00.35
Deerfield Management$19.59M7.524.13M0%+$00.05
Boxer Capital, LLC$12.17M4.682.57M0%+$00.25
BlackRock$5.2M21.1M+0.17%+$8,934.90<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.